Aclaris Therapeutics (STU:8AT) Net Interest Margin (Bank Only) %


STU:8AT Aclaris Therapeutics Inc STU:8AT
27 GF Score
Price €4.83
GF Value €0.39
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Aclaris Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:8AT
27GF Score
Aclaris Therapeutics Inc STU:8AT
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Aclaris Therapeutics (STU:8AT) Overvalued in 2026?

Based on GuruFocus' analysis, Aclaris Therapeutics stock appears to be overvalued. The current stock price of €4.83 is trading 1139% above its estimated GF Value™ of €0.39. GuruFocus considers Aclaris Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:8AT:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.39 vs. price of €4.83 (1139% above fair value)
  • GF Score™: 27/100 with 10 warning signs

No single metric tells the full story. See the STU:8AT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aclaris Therapeutics Business Description

Other Exchanges ACRS:USA0H8T:UK
Address 701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.
27GF Score

Get the complete analysis for STU:8AT

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.83
Price
€0.39
GF Value